Annual report pursuant to Section 13 and 15(d)

Note 17 - Segments - Segment Information (Details)

v3.20.1
Note 17 - Segments - Segment Information (Details) - USD ($)
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Revenue from contract with customer $ 38,000 $ 338,000
Grant and other revenue 631,208 846,830
Revenues, Total 657,826 1,169,351
Cost of revenue 6,667 96,636
Research and Development Expense, Total 5,338,267 4,221,881
Selling, general and administrative expenses, excluding depreciation and amortization [1] 6,130,897 7,547,750
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 144,512 150,385
Loss from operations [3] (10,962,517) (10,847,301)
Other income [4] 17,675 (5,321,270)
Provision for income taxes (707) 9,753
Loss from continuing operations (10,945,549) (16,158,818)
Loss from discontinued operations, net of tax effect (2,665) 1,449
Net loss (10,948,214) (16,114,316)
Total assets, net of depreciation and amortization 4,150,906 7,021,527
Capital expenditures 1,258 46,192
Gain on sale of discontinued operations, net of tax effect 43,053
UNITED STATES    
Total assets, net of depreciation and amortization 4,150,906 6,994,317
Non-US [Member]    
Total assets, net of depreciation and amortization 14,711
Royalty [Member]    
Revenue from contract with customer 16,665 15,347
License [Member]    
Revenue from contract with customer 9,953 307,174
Diagnostics Segment [Member]    
Grant and other revenue 384,776 494,997
Revenues, Total 411,394 817,518
Cost of revenue 6,667 96,636
Research and Development Expense, Total 4,795,445 3,064,115
Selling, general and administrative expenses, excluding depreciation and amortization [1]
Depreciation, Depletion and Amortization, Nonproduction, Total [2]
Loss from operations [3] (4,390,718) (2,343,233)
Other income [4]
Provision for income taxes (284) 1,413
Loss from continuing operations (4,391,002) (2,341,820)
Loss from discontinued operations, net of tax effect (2,665) 1,449
Net loss (4,393,666) (2,297,318)
Capital expenditures
Gain on sale of discontinued operations, net of tax effect   43,053
Diagnostics Segment [Member] | UNITED STATES    
Total assets, net of depreciation and amortization 55,229 91,425
Diagnostics Segment [Member] | Non-US [Member]    
Total assets, net of depreciation and amortization 14,330
Diagnostics Segment [Member] | Royalty [Member]    
Revenue from contract with customer 16,665 15,347
Diagnostics Segment [Member] | License [Member]    
Revenue from contract with customer 9,953 307,174
Therapeutics Segment [Member]    
Grant and other revenue 246,432 351,833
Revenues, Total 246,432 351,833
Cost of revenue
Research and Development Expense, Total 542,822 1,157,766
Selling, general and administrative expenses, excluding depreciation and amortization [1] 16,990 78,606
Depreciation, Depletion and Amortization, Nonproduction, Total [2]
Loss from operations [3] (313,380) (884,539)
Other income [4]
Provision for income taxes (20) 534
Loss from continuing operations (313,400) (884,005)
Loss from discontinued operations, net of tax effect
Net loss (313,400) (884,005)
Capital expenditures
Gain on sale of discontinued operations, net of tax effect  
Therapeutics Segment [Member] | UNITED STATES    
Total assets, net of depreciation and amortization 31,449 24,763
Therapeutics Segment [Member] | Non-US [Member]    
Total assets, net of depreciation and amortization
Therapeutics Segment [Member] | Royalty [Member]    
Revenue from contract with customer
Therapeutics Segment [Member] | License [Member]    
Revenue from contract with customer
Corporate Segment [Member]    
Grant and other revenue
Revenues, Total
Cost of revenue
Research and Development Expense, Total
Selling, general and administrative expenses, excluding depreciation and amortization [1] 6,113,907 7,469,144
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 144,512 150,385
Loss from operations [3] (6,258,419) (7,619,529)
Other income [4] 17,675 (5,321,270)
Provision for income taxes (403) 7,806
Loss from continuing operations (6,241,147) (12,932,993)
Loss from discontinued operations, net of tax effect
Net loss (6,241,147) (12,932,993)
Capital expenditures 1,258 46,192
Gain on sale of discontinued operations, net of tax effect  
Corporate Segment [Member] | UNITED STATES    
Total assets, net of depreciation and amortization 4,064,228 6,878,129
Corporate Segment [Member] | Non-US [Member]    
Total assets, net of depreciation and amortization 381
Corporate Segment [Member] | Royalty [Member]    
Revenue from contract with customer
Corporate Segment [Member] | License [Member]    
Revenue from contract with customer
[1] General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments, other than those expenses directly incurred by MT.
[2] Depreciation and amortization is reflected in selling, general and administrative expenses ($144,512 and $150,385 for the years ended December 31, 2019 and 2018, respectively).
[3] Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments.
[4] Amounts consist primarily of losses on debt extinguishment, interest income and interest expense, which are not currently allocated to our individual reportable segments.